Form 4: Atossa Therapeutics SVP, Finance and Accounting, Heather Rees, Reports Stock Option Grant

Heather Rees, SVP, Finance and Accounting at Atossa Therapeutics, reports the acquisition of stock options.

Summary

• On June 27, 2024, Heather Rees, SVP, Finance and Accounting at Atossa Therapeutics, reported the acquisition of 577,700 stock options.
• The options have an exercise price of $1.05 per share.
• The options vest quarterly over 24 months, contingent upon continued service to Atossa Therapeutics.
• The options expire on June 27, 2034.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to stock option grants. It's neutral in tone and doesn't contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of stock options aligns the interests of the SVP, Finance and Accounting with the long-term success of Atossa Therapeutics.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the pharmaceutical and biotechnology industries.
• Companies like Amgen, Gilead Sciences, and Biogen routinely use stock options to incentivize their executives.
• The vesting schedule of 24 months is fairly typical for such grants.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised in the future.

Key Dates